0.3722

5.96% -0.0236

After Hours: .38 0.0078 +2.10%

Biorestorative Therapies Inc (BRTX)

Overview News Price History Financials Discussions Forecast Stock Split

Biorestorative Therapies Inc stock is traded at $0.3722, with a volume of 91,749. It is down -5.96% in the last 24 hours and down -8.10% over the past month. BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

Previous Close:

$0.3958

Open:

$0.382

24h Volume:

91,749

Relative Volume:

0.01

Market Cap:

$9.48M

Revenue:

$357.90K

Net Income/Loss:

$-11.06M

P/E Ratio:

-0.3323

EPS:

-1.1201

Net Cash Flow:

$-11.90M

1W Performance:

-1.01%

1M Performance:

-8.10%

6M Performance:

-68.46%

1Y Performance:

-75.51%

1-Day Range:

$0.365

$0.394

1-Week Range:

$0.365

$0.4142

52-Week Range:

$0.1593

$1.89

Biorestorative Therapies Inc Stock (BRTX) Company Profile

Name

Biorestorative Therapies Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

(631) 760-8100

Address

40 MARCUS DRIVE, MELVILLE

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

BRTX's Discussions on Twitter

Compare BRTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BRTX Biorestorative Therapies Inc	0.3722	10.08M	357.90K	-11.06M	-11.90M	-1.1201
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Biorestorative Therapies Inc Stock (BRTX) Latest News

Jul 03, 2026

Here's why Biorestorative Therapies (BRTX) looks ripe for bottom fishing - MSN

Jul 03, 2026

Jun 30, 2026

BioRestorative Therapies, Inc.'s Equity Buyback announced on August 12, 2025, has expired. - marketscreener.com

Jun 30, 2026

Jun 28, 2026

Enterprise value to EBITDA forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView

Jun 28, 2026

Price to earnings forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView

Jun 28, 2026

Price to earnings forward of BioRestorative Therapies, Inc. – TRADEGATE:9OF - TradingView

Jun 28, 2026

Jun 27, 2026

BioRestorative (NASDAQ:BRTX) Gains Penny Stock Attention - Kalkine Media

Jun 27, 2026

Enterprise value to revenue forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView

Jun 27, 2026

Enterprise value to revenue forward of BioRestorative Therapies, Inc. – TRADEGATE:9OF - TradingView

Jun 27, 2026

Price to book forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView

Jun 27, 2026

Price to sales forward of BioRestorative Therapies, Inc. – TRADEGATE:9OF - TradingView

Jun 27, 2026

Price to book forward of BioRestorative Therapies, Inc. – TRADEGATE:9OF - TradingView

Jun 27, 2026

Jun 26, 2026

BioRestorative Therapies Announces Completion of BRTX-100 Manufacturing for Phase 2 Clinical Trial - Quiver Quantitative

Jun 25, 2026

BioRestorative finishes BRTX-100 Phase 2 supply in-house - Stock Titan

Jun 25, 2026

Jun 24, 2026